Search PubMed⌕ Search

Biomedical subjects

H Schwartz

Publications and source records attributed to H Schwartz.

168 records · Page 10Linked to original sources
PubMedDate not supplied

A computerized hospital maintenance system.

The Biomedical Instrumentation Department at Thomas Jefferson University Hospital maintains most of the clinical equipment owned by the hospital and provides support to six other hospitals, as well. In order to document these services, a computerized support system has been developed. This system maintains the inventory of equipment, documents the occurrence of repair and preventive maintenance procedures, generates lists of items due for maintenance and inspection, and prints reports and summaries of all activities performed by department staff. The system was designed for ease of use and requires a minimum of training for personnel who use it.

Computers↗
PubMedDate not supplied

Coccidioidomycosis of the larynx in infants and adults.

Coccidioidomycosis is a fungal disease endemic to the southwestern United States. The primary form of the disease is relatively benign and many patients, after exposure by inhalation of the sapyrophytic form of the organism, convert from negative to positive skin testing without significant clinical symptoms. The less common disseminated form represents a serious life-threatening disease and can present with granulomatous changes in the larynx. The authors' experience with disseminated coccidioidomycosis presenting in the larynx of adults and infants successfully treated with amphotericin B are presented and discussed.

Amphotericin B↗
PubMedDate not supplied

Intranasal budesonide aqueous pump spray (Rhinocort Aqua) for the treatment of seasonal allergic rhinitis. Rhinocort Aqua Study Group.

To determine the relative efficacy, compare the incidence of adverse events, and ascertain the systemic glucocorticoid effect of the nasal application of several doses of budesonide, 406 patients with seasonal ragweed-induced allergic rhinitis were randomized in a double-blind, parallel group design to receive intranasal budesonide aqueous pump spray (Rhinocort Aqua) 32 micrograms, 64 micrograms, 128 micrograms, 256 micrograms, or placebo once daily for 4 weeks. A total of 231 adults and 175 children participated in the study conducted at 14 centers in two geographic regions, the Midwest and the Northeast United States, during the 1994 ragweed season. Pollen counts were collected at each site by the Rotorod method. The primary efficacy parameter was the change from baseline nasal index score (NIS) for the overall study population--defined as the sum of scores for nasal congestion, runny nose, and sneezing. The study was powered only to evaluate the overall study population for statistical significance. Significant differences in NIS were observed in each active treatment group compared with placebo (p < or = 0.003). Compared with placebo, budesonide aqueous spray significantly reduced individual symptoms of runny nose and sneezing at all doses (p < or = 0.008), and nasal congestion and nasal itching at all doses except 64 micrograms (p < or = 0.022). In the Midwest pollen belt where the 1994 ragweed season was representative of a typical pollen season, it was possible to establish a dose-response relationship for comparison of budesonide aqueous spray 256 micrograms versus 32 micrograms (p = 0.017). The incidence of adverse events was similar between budesonide aqueous-treated and placebo-treated patients. Importantly, there was no effect of budesonide aqueous spray on basal or ACTH-stimulated plasma cortisol levels in either adults or children at the end of 4 weeks of treatment. Intranasal budesonide aqueous pump spray, administered once daily, was efficacious and was generally well tolerated in both adults and children with seasonal allergic rhinitis.

Administration, Intranasal↗
PubMedDate not supplied

Clinical observation: Beau's lines on fingernails after deep saturation dives.

Transverse furrows, or Beau's lines, were noted in the fingernails of all 6 divers following a deep saturation dive to apressure equal to 1100 feet (335 meters) ofsea water (3,370 kPa), and in 2 of6 divers following a similar dive to 1000 feet (305 meters) of sea water (3,164 kPa). Both dives took place at the Ocean Simulation Facility of the Navy Experimental Diving Unit in Panama City, Florida. The divers breathed a partial pressure of 0.40 - 0.44 atm abs (40.5 - 44.6 kPa) oxygen, with the balance helium, during most of the time under pressure. All divers performed hard work on bicycle ergometers during the dives. Four of the divers on the first dive were treated during the dive for pain-only decompression sickness. Beau's lines have been reported in numerous medical conditions such as typhus, rheumatic fever, malaria, myocardial infarction, and other severe metabolic stresses. To the author's knowledge this is the first report of Beau's lines associated with saturation diving.

Decompression↗